Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00887198 · ClinicalTrials.gov registry record · Phase 3
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,088
- Enrollment target
- 20
- Study locations
NCT00887198 is a Phase 3 study of Prostate Cancer that has completed, run by Janssen Research & Development. The registered enrollment target is 1,088 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT00887198, a Phase 3 study of Prostate Cancer, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,088 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prednisone
- DRUG Abiraterone acetate
Study Locations (20)
California
- - Bellflower
- - Los Angeles
- - Marina del Rey
- - Sacramento
- - San Diego
- - San Francisco
- - Stanford
Florida
- - Boca Raton
- - Fort Myers
- - Gainesville
Louisiana
- - Metairie
- - New Orleans
Alabama
- - Birmingham
Arizona
- - Tucson
Colorado
- - Aurora
Connecticut
- - New Haven
Georgia
- - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,088 participants |
| Start Date | 2009-04-28 |
| Est. Completion | 2017-05-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00887198
The ClinicalTrials.gov registry entry for NCT00887198 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,088 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (79% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00887198 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT00887198 about?
NCT00887198 is a clinical study titled "Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer". This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC).
What is the current status of trial NCT00887198?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,088 participants. The study started on 2009-04-28. Estimated completion is 2017-05-25.
What conditions does trial NCT00887198 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00887198?
The interventions under investigation include: Placebo (DRUG), Prednisone (DRUG), Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT00887198?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00887198 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.